Skip to content
Peptide research

PACAP

Also known as PACAP-38 · Pituitary Adenylate Cyclase-Activating Peptide
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

PACAP is a naturally occurring 38-amino-acid neuropeptide marketed for neuroprotection after stroke and brain injury. Evidence is almost entirely animal-based: moderate data show reduced stroke damage, while Parkinson's and Huntington's claims rest on weaker findings, and human evidence is essentially absent. Its mechanism reliably triggers migraine and low blood pressure. Not an approved drug in the US; supply is unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is a highly conserved endogenous neuropeptide belonging to the secretin/glucagon/VIP superfamily. Discovered in 1989 from ovine hypothalamic extracts, PACAP exists in two biologically active forms — PACAP38 (38 amino acids) and PACAP27 (27 amino acids) — with PACAP38 being the predominant form in mammalian tissues. PACAP is widely distributed throughout the central and peripheral nervous systems and acts through three G-protein coupled receptors: PAC1R (which it binds with much higher affinity than VIP), VPAC1R, and VPAC2R.

PACAP is regarded as one of the most potent endogenous neuroprotective agents identified to date. It activates multiple prosurvival signaling cascades including the cAMP/PKA, ERK/MAPK, and PI3K/Akt pathways, and upregulates expression of anti-apoptotic proteins such as Bcl-2 while suppressing cytochrome c release from mitochondria. Research has demonstrated that PACAP provides robust protection against ischemic brain injury, excitotoxicity, oxidative stress, and neurodegenerative disease models including Huntington's, Parkinson's, and Alzheimer's. It also promotes IL-6-mediated neuroprotection via the STAT3 signaling axis.

Beyond neuroprotection, PACAP plays important roles in neurodevelopment, circadian rhythm regulation, stress responses, immune modulation, and vasodilation. Its involvement in migraine pathophysiology has attracted clinical interest, with PACAP infusion shown to reliably trigger migraine-like attacks in susceptible individuals. This has led to the development of anti-PACAP antibodies as migraine therapeutics, validating the peptide's clinical relevance. PACAP's remarkably broad protective profile and extremely high evolutionary conservation (97% identical between mammals and amphibians) underscore its fundamental biological importance.

How it works in the body

Pituitary Adenylate Cyclase-Activating Peptide binds PAC1, VPAC1, and VPAC2 receptors to activate adenylate cyclase and increase intracellular cAMP. This triggers powerful neuroprotective cascades including anti-apoptotic signaling (BCL-2 upregulation), antioxidant enzyme induction, and neurotrophic factor release. It is one of the strongest endogenous neuroprotective agents known.

Research overview

PACAP has been the subject of extensive preclinical and translational research since its discovery in 1989. Over 3,000 PubMed-indexed publications document its neuroprotective, neuroendocrine, and immunomodulatory properties. In animal models of focal cerebral ischemia, PACAP38 intracerebroventricular infusion at picomolar to nanomolar concentrations reduced infarct volume by 40-60% and improved neurological deficit scores (Ohtaki et al., PNAS 2006). PACAP-null mice show larger infarct volumes and worse neurological outcomes, confirming endogenous neuroprotective function. The peptide also protects striatal neurons in Huntington's disease models via PAC1R-dependent activation of ERK and Akt, upregulating BDNF, CBP, and c-fos expression (Soles-Tarres et al., Frontiers in Pharmacology 2022). In Parkinson's disease models, PACAP protects dopaminergic neurons from 6-OHDA and MPTP toxicity. Clinical research has focused primarily on PACAP's role in migraine; the cited trial reported headache in 11 of 12 migraine patients and migraine-like attacks in 7 of 12. This has validated PACAP as a drug target, with Eli Lilly developing LY3451838, a monoclonal antibody against PACAP, which completed Phase 2 clinical trials for migraine prevention (Johnson et al., Cephalalgia 2025). Additional research areas include traumatic brain injury, retinal degeneration, neurodevelopmental disorders, and metabolic regulation.

Who researches PACAP?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Migraine/headache induction via vasodilation

    High

    Schytz et al., Brain 2009, PACAP38 induces migraine-like attacks in patients with migraine without aura (PMID 19052139); Amin et al., Brain 2014 (PACAP38-induced cranial artery dilatation and migraine)

  • Systemic vasodilation and hypotension

    Moderate

    Birk et al., Regul Pept 2007 (intravenous PACAP38 hemodynamics in healthy volunteers); Amin et al., Brain 2014

  • Very short half-life limiting therapeutic window

    High

    Zhu et al., J Biol Chem 2003 (DPP-IV cleavage/in vivo metabolism of PACAP-(1-38)); Vaudry et al., Pharmacol Rev 2009

Interaction summary(7)

Rated by direction with this peptide

  • Antihypertensives and vasodilators (nitrates, PDE5 inhibitors, calcium channel blockers, alpha-blockers)

    CautionModerate

    PACAP is itself a potent vasodilator that lowers mean arterial pressure and raises heart rate in controlled human infusion studies, so using it with other vasodilating agents plausibly adds hypotension, flushing and reflex tachycardia. The PACAP hemodynamic effect is human-documented; the combination itself has never been formally studied.

    Human PACAP38 infusion hemodynamics: Birk et al., Regul Pept 2007; Amin et al., Brain 2014

  • Anti-PACAP / anti-PAC1 monoclonal antibodies (Lu AG09222, AMG 301)

    CautionLow

    This is direct pharmacologic antagonism of the exact ligand-receptor axis PACAP acts on, so each would be expected to blunt or abolish the other's effect. The consequence is loss of intended effect, not toxicity, which is a Low-severity interaction even though the mechanism is the most certain one in this table.

    AMG 301 (anti-PAC1) phase 2 migraine prevention trial reported by Ashina and colleagues, Cephalalgia 2021; Lundbeck Lu AG09222 (anti-PACAP) phase 2 migraine prevention program

  • DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin)

    CautionTheoretical

    PACAP38/PACAP27 are DPP-4 substrates, so DPP-4 inhibition would slow N-terminal cleavage and prolong PACAP exposure. The actionable consequence is amplified vasodilation, flushing and headache, not a benefit — and prolonged exposure also alters the balance of the PACAP(3-38) cleavage fragment, itself a PAC1 antagonist. Mechanism-based inference only; never tested clinically.

    Zhu et al., J Biol Chem 2003 (DPP-IV cleavage of PACAP); mechanistic inference, no clinical interaction data

  • Insulin secretagogues and insulin (sulfonylureas, GLP-1 agonists, insulin)

    CautionTheoretical

    PACAP acts on PAC1/VPAC receptors on pancreatic beta cells as a largely glucose-dependent insulin secretagogue, raising a mechanistic hypoglycemia concern when combined with other insulinotropic therapy. Glucose-dependence makes standalone hypoglycemia unlikely; the concern is additive with sulfonylureas or insulin, which are not glucose-dependent. No clinical interaction reports exist.

    Ahren/Filipsson group work on PACAP as a pancreatic insulinotropic peptide (rodent studies plus small human infusion work) — topic-level descriptor; no verified interaction citation

  • Triptans (sumatriptan)

    ProtectiveLow

    Sumatriptan constricts cranial arteries and reverses PACAP38-induced extracerebral vasodilatation in human provocation work, making it a plausible rescue agent rather than a hazard. Evidence that it prevents the delayed migraine-like attack itself is weak, so this should be read as 'not a dangerous combination, possibly useful as rescue' rather than as demonstrated efficacy against PACAP-triggered migraine.

    Human PACAP38 provocation studies with sumatriptan (Ashina/Amin group) — descriptor only, without journal and year

  • CGRP-targeting migraine drugs (erenumab, fremanezumab, gepants)

    NeutralLow

    Claim narrowed. PACAP and CGRP appear to act through at least partly independent headache-signaling pathways, so co-exposure is unlikely to be strongly additive in either direction — but the practical point is the conservative one: CGRP blockade should not be assumed to protect against PACAP-induced headache. The specific assertion that erenumab fails to block PACAP38-induced headache is reported in the Ashina group's provocation literature but could not be citation here, so it is stated as an expectation rather than an established result.

    Human PACAP38 provocation studies under CGRP-pathway blockade (Ashina group, Brain, circa 2021) — citation details unconfirmed

  • Platinum chemotherapy and aminoglycosides (cisplatin, gentamicin)

    CautionTheoretical

    The underlying data are real but entirely rodent: PACAP reduces cisplatin- and aminoglycoside-associated cochlear and renal/neuronal damage via anti-apoptotic PAC1/Bcl-2 signaling. Nothing has been tested alongside human oncology regimens, and a broadly anti-apoptotic, Bcl-2-upregulating peptide given during cytotoxic chemotherapy carries a theoretical counter-risk of protecting tumor cells and blunting treatment. Anyone on active cancer therapy should treat this as a reason for oncologist consultation, not a reason to add PACAP.

    Reglodi/Tamas group rodent otoprotection and nephroprotection studies (Regul Pept / J Mol Neurosci) — descriptor only; tumor-cytoprotection concern is mechanistic inference, not a reported finding

Known risks(3)

  • Migraine/headache induction via vasodilation

    Moderate to Severe

    In the cited study, 11 of 12 migraine patients developed headache, while 7 of 12 developed migraine-like attacks. Healthy participants also developed headache. This is mediated by vasodilation of cerebral and meningeal blood vessels through PAC1R and VPAC receptor activation.

  • Systemic vasodilation and hypotension

    Moderate

    PACAP is a potent vasodilator that can cause flushing, decreased blood pressure, and increased heart rate when administered systemically. This limits achievable therapeutic doses via IV or subcutaneous routes.

  • Very short half-life limiting therapeutic window

    Pharmacokinetic Limitation

    PACAP has a circulating half-life of only 2-10 minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other peptidases. Sustained delivery methods or stable analogs are required for therapeutic applications.

Drug interactions(3)

  • Antihypertensive agents

    PACAP is a potent vasodilator; co-administration with blood pressure-lowering medications could cause additive hypotension. Blood pressure monitoring recommended.

  • Migraine medications (triptans, CGRP inhibitors)

    PACAP triggers migraine-like attacks; combining with migraine therapeutics may produce unpredictable effects. CGRP antibodies do not block PACAP-induced migraine, suggesting independent pathways.

  • DPP-IV inhibitors (sitagliptin, saxagliptin)

    DPP-IV is a major enzyme responsible for PACAP degradation. DPP-IV inhibitors could potentially extend PACAP's half-life and increase its biological effects, including vasodilation.

Research & benefits

Evidence base

Evidence Level
Strong Preclinical / Early Clinical
Total Studies
3000
Human Studies
500

PACAP has an exceptionally strong preclinical evidence base with >3,000 publications demonstrating neuroprotection across stroke, traumatic brain injury, neurodegeneration, and retinal disease models. Clinical research has primarily focused on PACAP's role in migraine pathophysiology, where it has been validated as a therapeutic target. Anti-PACAP-ligand antibody LY3451838 (Eli Lilly) completed Phase 2 for migraine prevention. Direct therapeutic use of PACAP for neuroprotection has not yet entered clinical trials due to challenges with delivery and its vasodilatory/migraine-triggering side effects.

Researched for(6)

Rated by confidence in the evidence

  • Potent neuroprotection against ischemic brain injury (40-60% infarct reduction in animal models)

    Medium

    Consistently reduces stroke damage in rodent models over 25 years of study; no human trials exist.

    Reglodi et al., Stroke 2000 (PACAP38 in transient MCAO in rats); Ohtaki et al., PNAS 2006 (PACAP/PAC1 signaling in cerebral ischemia)

  • Protection of striatal neurons in Huntington's disease models via PAC1R/ERK/Akt signaling

    Low

    Protects striatal neurons in a small number of Huntington's mouse studies; no human data.

    Cabezas-Llobet et al., Mol Neurobiol 2018 (PACAP in R6/1 HD mice)

  • Anti-apoptotic effects via Bcl-2 upregulation and cytochrome c suppression

    Medium

    Well-replicated mechanism in animal and cell studies; not yet confirmed as a clinical benefit.

    Vaudry et al., Pharmacol Rev 2009 (PACAP and its receptors: 20 years after the discovery) — review-level support; individual cerebellar granule cell apoptosis studies

  • Neuroprotection in Parkinson's disease models (dopaminergic neuron survival)

    Low

    Protects dopamine neurons across several rodent Parkinson's models; animal-only, no clinical trials.

    Reglodi group publications on PACAP in 6-OHDA and MPTP parkinsonian rodent models (Behav Brain Res / Regul Pept) — descriptor only; specific volume/page not verified

  • Upregulation of neurotrophic factors (BDNF, NGF, NT-3) in brain tissue

    Low

    BDNF induction is reasonably supported; NGF and NT-3 evidence is thinner and preliminary.

    Cabezas-Llobet et al., Mol Neurobiol 2018 (BDNF restoration in HD mice); broader PACAP-CREB neurotrophin induction literature (no single definitive citation for the NGF/NT-3 components)

  • Anti-inflammatory effects through modulation of microglial activation and cytokine balance

    Medium

    Extensive animal data show reduced inflammatory markers; no human anti-inflammatory outcome studies.

    Delgado & Ganea and colleagues, VIP/PACAP immunomodulation literature (J Immunol and review articles including Amino Acids 2013) — author/topic descriptor, without identifiers

Benefits(6)

  • Potent neuroprotection against ischemic brain injury (40-60% infarct reduction in animal models)

    Ohtaki et al., PNAS 2006; Reglodi et al., Neurochem Int 2011; multiple preclinical studies

  • Protection of striatal neurons in Huntington's disease models via PAC1R/ERK/Akt signaling

    Soles-Tarres et al., Front Pharmacol 2022 (in vitro + R6/1 mouse model)

  • Anti-apoptotic effects via Bcl-2 upregulation and cytochrome c suppression

    Ohtaki et al., PNAS 2006 (PACAP-null mouse model, focal ischemia)

  • Neuroprotection in Parkinson's disease models (dopaminergic neuron survival)

    Reglodi et al., J Mol Neurosci 2004; Dejda et al., Neuroscience 2005

  • Upregulation of neurotrophic factors (BDNF, NGF, NT-3) in brain tissue

    Dejda et al., Neuropeptides 2011; multiple preclinical studies

  • Anti-inflammatory effects through modulation of microglial activation and cytokine balance

    Delgado et al., FASEB J 2003; multiple immunological studies

Key studies(4)

  1. Pituitary adenylate cyclase-activating polypeptide (PACAP) prevents neuronal cell death after focal ischemia via IL-6 signaling

    Preclinical (PACAP-null mice, focal ischemia)Multiple cohorts of WT, PACAP+/-, PACAP-/-, and IL-6-null miceAcute ischemia model

    Ohtaki H, Nakamachi T, Dohi K, et al.

    Proceedings of the National Academy of Sciences (PNAS)

    2006

    PACAP-deficient mice showed larger infarct volumes and worse neurological deficits after focal ischemia. PACAP38 injection reduced infarct volume and improved outcomes in WT and PACAP-null mice via IL-6/STAT3/ERK signaling. PACAP's neuroprotection was abolished in IL-6-null mice, establishing the PACAP-IL-6 neuroprotective axis.

  2. PACAP Protects Striatal Cells and Improves Motor Function in Huntington's Disease Models: Role of PAC1 Receptor

    Preclinical (cell + animal model)STHdh cell lines + R6/1 mice24 hours in vitro; 7 days of treatment in 18-week-old mice

    Soles-Tarres I, Cabezas-Llobet N, Lefranc B, et al.

    Frontiers in Pharmacology

    2022

    PACAP treatment protected striatal cells expressing mutant huntingtin from apoptosis via PAC1R-dependent activation of ERK, Akt, and increased BDNF/CBP expression. In R6/1 mice, PACAP intranasal administration improved motor coordination and reduced striatal neurodegeneration.

  3. Lee EH, Seo SR.

    BMB Reports

    2014

    Comprehensive review of PACAP's neuroprotective mechanisms including anti-apoptotic effects via cAMP/PKA, ERK/MAPK, and PI3K/Akt pathways. Describes protective effects in stroke, Parkinson's, Huntington's, Alzheimer's, and retinal degeneration models.

  4. Johnson MP, Krikke-Workel J, Patel CN, et al.

    Cephalalgia

    2025

    LY3451838, an anti-PACAP monoclonal antibody, failed to demonstrate efficacy over placebo for migraine prevention in this Phase 2a proof-of-concept trial. The study did not meet its primary endpoint, raising questions about whether targeting the PACAP ligand alone is sufficient for migraine prevention.

Regulation & availability

Why researchers look at it

PACAP is one of nature's most powerful neuroprotective molecules, activating multiple survival pathways simultaneously to shield neurons from stroke, trauma, and neurodegeneration. While direct therapeutic use remains challenging, understanding PACAP biology is driving the next generation of brain-protective therapies.

FDA status
PACAP is not FDA-approved and is not eligible for compounding in the US. PACAP is used experimentally in migraine-provocation studies. LY3451838 is a separate anti-PACAP antibody whose Phase 2 migraine study ended in November 2022; results were published in 2025.
WADA status
Not individually named in the 2026 list. This does not establish permission: exogenous PACAP without governmental human therapeutic approval falls under S0 unless another section applies. Endogenous occurrence is not an exemption; obtain an authoritative classification.
Prescribability
No; not FDA-approved for any indication
Availability
PACAP is not available as an FDA-approved medication. Anti-PACAP antibodies are in clinical development for migraine (e.g., Eli Lilly's LY3451838). Direct therapeutic use of PACAP itself is limited by its vasodilatory effects and short half-life in circulation.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(7)

  1. 1989
    PACAP first isolated from ovine hypothalamic extracts by Miyata et al.
  2. 1990s
    Three PACAP receptors (PAC1R, VPAC1R, VPAC2R) identified and cloned
  3. 2006
    Landmark PNAS study demonstrates PACAP-IL-6 neuroprotective axis in ischemia
  4. 2012
    PACAP infusion validated as migraine provocation model in clinical studies
  5. 2020
    Anti-PAC1R antibody AMG 301 Phase 2 trial found no efficacy difference from placebo.
  6. 2022
    PACAP shown to protect striatal neurons in Huntington's models via intranasal route
  7. 2024-2025
    LY3451838 anti-PACAP-ligand antibody Phase 2 results published in 2025; the study ended in November 2022.

Sources & FAQs

Research sources(6)

Frequently asked questions(4)

What makes PACAP one of the most potent neuroprotective peptides?

PACAP simultaneously activates multiple prosurvival signaling pathways — cAMP/PKA, ERK/MAPK, and PI3K/Akt — while upregulating anti-apoptotic proteins like Bcl-2 and neurotrophic factors like BDNF. It also suppresses neuroinflammation through microglial modulation. This multi-pathway engagement provides broader protection than agents targeting a single mechanism. Its neuroprotective effects have been confirmed across stroke, Parkinson's, Huntington's, Alzheimer's, and traumatic brain injury models.

Why isn't PACAP used directly as a therapeutic drug?

PACAP has a very short half-life in circulation (minutes) and potent vasodilatory effects that trigger migraine-like headaches in most people when administered intravenously. These side effects, combined with delivery challenges for reaching the brain, have limited its direct therapeutic use. Research is focused on developing stable analogs, targeted delivery methods (intranasal), and receptor-specific approaches to harness its neuroprotective benefits.

How is PACAP related to migraine research?

The cited trial found migraine-like attacks in 7 of 12 migraine patients after PACAP38 infusion; 11 of 12 reported headache. This discovery validated the PACAP/PAC1R axis as a migraine target and led to development of anti-PACAP antibodies by Eli Lilly and others. Interestingly, the same peptide that triggers migraine is also one of the brain's most powerful protective agents — highlighting the complexity of neuropeptide signaling.

What is the difference between PACAP38 and PACAP27?

Both are bioactive forms of PACAP. PACAP38 (38 amino acids) is the predominant endogenous form and contains the full PACAP27 sequence at its N-terminus plus an additional 11 C-terminal residues. PACAP38 has higher affinity for the PAC1R receptor and is more widely studied for neuroprotection. PACAP27 shares 68% sequence homology with VIP and binds VPAC receptors with similar affinity.